Breathe Well Live Well
|
Exclusive – Glaxo R&D boss says Advair safe from generics
Reuters UK L) $8 billion (5 billion pounds)-a-year Advair treatment for asthma and smoker's cough can hope to capture only "a very small fraction" of its sales, the British drugmaker's research chief said on Tuesday. Advair, which uses an inhaler to deliver two … |
View full post on asthma – Google News
|
Goldman Sachs downgrades Glaxo to "sell"
BusinessWeek A Goldman Sacks analyst says GlaxoSmithKline's stock is overvalued as the British drugmaker prepares to face lower sales of its best-selling product, the asthma inhaler Advair. Goldman analyst Mark Beards notes the London-based drugmaker's shares have … Search Stocks To Watch Today Goldman Sachs downgrades Glaxo to "sell" |
View full post on asthma – Google News
|
Goldman Sachs downgrades Glaxo to "sell"
Forbes AP , 05.31.11, 10:57 AM EDT WASHINGTON — A Goldman Sacks analyst says GlaxoSmithKline's stock is overvalued as the British drugmaker prepares to face lower sales of its best-selling product, the asthma inhaler Advair. Goldman analyst Mark Beards notes … Goldman Downgrades GSK as Growth Won't Support Valuation Goldman Sachs downgrades Glaxo to "sell" |
View full post on asthma – Google News
|
Glaxo, Theravance report Relovair safety data
BusinessWeek GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study. … GSK and Theravance announce combination ICS/LABA Phase II results in the … GlaxoSmithKline Reports Positive Results For Phase II Trial Of Relovair In … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News